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INTRODUCTION 
We are faced with over 200 nutrition decisions every day1, and often turn to 
professional health organizations for dietary guidance. Currently, there is much discussion 
about the role of added sugars in metabolic disease and the use of artificial sweeteners (AS) as 
a safe alternative. The Academy of Nutrition and Dietetics (AND), American Heart Association 
(AHA), American Diabetes Association (ADA), and the US Department of Agriculture (USDA) 
have all determined that based on available evidence, including GRAS status by the FDA, 
artificial sweeteners are safe to consume as part of a healthy and well-rounded diet2-5. The 
Academy of Nutrition and Dietetics holds the position that “consumers can safely enjoy a range 
of nutritive and nonnutritive sweeteners when consumed within an eating plan that is guided 
by current federal nutrition recommendations, such as the Dietary Guidelines for Americans”2. 
According to the 2015-2020 Dietary Guidelines for Americans however, much of the United 
States does not follow an eating pattern that follows the DGAs6. Instead, the majority of 
Americans consume a “Western” diet high in total calories, refined grains, meat, added sugars, 
saturated fat, and sodium, and low in vegetables, fruit, dairy, and oils. AS may not play a 
healthy role in the context of a largely Western diet. 
The recommendations of these health organizations are used to guide the clinical 
management of diabetes, a chronic disease affecting 9.3% of the United States population7. 
Type 2 diabetes (T2D) is a form of diabetes in which insulin stops working properly in the body, 
known as insulin resistance, leading to chronic hyperglycemia8. In the early stages, often 
referred to as “pre-diabetes”, the pancreas is able to produce extra insulin to compensate for 
chronically elevated blood sugar levels. Over time, the pancreas cannot keep up with the 
demand, and can no longer produce enough insulin to maintain normal blood sugar levels9. Left 
untreated, people with diabetes may develop serious complications such as heart disease and 
stroke, blindness, nerve damage, leg amputation, and kidney failure9. The 29.1 million people in 
the US with diabetes7 are encouraged by the ADA to use artificial sweeteners as a replacement 
for all sugar sources: tabletop sweeteners, baking ingredients, processed foods, etc10. 
Consumption of AS in place of caloric sweeteners is suggested to help manage blood sugar, 
weight, and sweet cravings10,4. 
Despite the relative consistency of recommendations from national health 
organizations, the safety of AS consumption is controversial12-14. For every study or review that 
indicates AS are safe and healthy to consume15,16 there is an opposing study that concludes the 
evidence is inconclusive17,18. Occasionally, reviews that endorse the consumption of AS are 
written by consultants for, and board members of the very food and beverage companies that 
use these products19. In addition, a growing body of literature indicates that AS may actually be 
harmful, potentially causing insulin resistance and weight gain20-22. Some of the evidence about 
potential harm stems from large population-based studies, but other mechanistic data come 
from animal studies, which are not formally considered by recommending bodies. For example, 
the positions of the AND, ADA, and AHA on AS consumption are based strictly on evidence 
gleaned exclusively from human studies2,3,5.  
 Given the prevalence of diabetes in the US and the severity of its complications, it is 
important for clinical practitioners and dietitians to use the most up-to-date research to guide 
nutrition recommendations for patients living with this chronic disease. Given the scope of the 
medical literature, practitioners will reasonably rely on the data summaries and formal 
recommendations of national organizations. In this review we will 1) qualitatively asses the 
evidence cited by the AND, AHA, and ADA in their recommendations for AS consumption and 2) 
evaluate the rapidly growing body of literature on AS that may run counter to conclusions of 
studies forming the basis of nutrition recommendations. We will end with a discussion of the 
implications these findings have for individuals living with diabetes as well as the dietitians 
charged with their care.  
 
 
METHODS 
The position papers of the AND, ADA, and AHA were reviewed to identify literature used 
to inform the organization’s assessment of the relationship between artificial sweeteners and 
T2D (and its risk factors including weight gain and glycemic response). To identify current 
literature not reviewed by the ADA, AND, and AHA, keyword searches performed in PubMed 
included: artificial sweeteners, nonnutritive sweeteners, gut microbiome, gut microbiota, 
insulin resistance, type II diabetes, and weight. This review was not limited to human studies. 
Literature before the year 2005 was not included given the inclusion of older articles in the 
recommendations and the rapid growth of literature in the field over the past 10 years.  
 
 
RESULTS AND DISCUSSION 
 
Table 1: AND, ADA, AHA Positions on Artificial/Nonnutritive/Non-caloric Sweeteners 
 
Health Organization Publication Risk Factors Reviewed Position 
Academy of Nutrition and 
Dietetics 
(AND) 
Position of the Academy of Nutrition and 
Dietetics: Use of Nutritive and Nonnutritive 
Sweeteners (2012). 
 
Systematic and independent review of human 
studies and information from the AND Evidence 
Analysis Library. 
Energy balance (weight gain) 
in a calorie-restricted or ad 
libitum diet, appetite, food 
intake, glycemic response, 
diabetes management, 
hyperlipidemia, adverse 
effects in the general and 
special populations. 
“It is the position of the Academy of Nutrition 
and Dietetics that consumers can safely enjoy a 
range of nutritive and nonnutritive 
sweeteners when consumed within an eating 
plan that is guided by current federal 
nutrition recommendations, such as the Dietary 
Guidelines for Americans and the Dietary 
Reference Intakes, as well as individual health 
goals and personal preference.” (AND, 2012). 
American Diabetes 
Association 
(ADA) 
Nutrition Therapy Recommendations for the 
Management of Adults with Diabetes: Position 
statement of the American Diabetes Association 
(2014). 
 
Systematic Review of human studies. 
Overall reduction of caloric 
and carbohydrate intake. 
“Use of nonnutritive sweeteners has the 
potential to reduce overall calorie and 
carbohydrate intake if substituted for caloric 
sweeteners without compensation by intake of 
additional calories from other food sources.” 
(Evert, 2014).  
American Heart 
Association & American 
Diabetes Association 
(AHA/ADA) 
Nonnutritive Sweeteners: Current Use and 
Health Perspectives. A Scientific Statement from 
the American Heart Association and the 
American Diabetes Association (2012).  
 
Systematic review of human studies.  
Appetite, hunger, energy 
intake, energy intake 
compensation, 
appetite/preference for sweet 
taste, body weight, 
cardiometabolic syndrome, 
coronary heart disease, 
diabetes mellitus, glycemic 
response. 
“There are insufficient data to determine 
conclusively whether the use of NNS to displace 
caloric sweeteners in beverages and foods 
reduces added sugars or carbohydrate intakes, 
or benefits cardiometabolic risk factors. The 
substitution of added sugars with NNS may be 
used in a structured diet to achieve modest 
energy intake reductions and weight loss. 
Successful reduction in energy intake requires 
that there is incomplete compensation of energy 
reduction from the use of NNS containing 
beverages and/or foods. When used judiciously, 
NNS could facilitate reductions in added sugars 
intake, thereby resulting in decreased total 
energy and weight loss/weight control, and 
promoting beneficial effects on related 
metabolic parameters. However, these potential 
benefits will not be fully realized if there is a 
compensatory increase in energy intake from 
other sources.” (Gardner, 2012). 
 
 
 
 
 
 
 
Table 2: Literature not Considered by AND, ADA, and AHA in their Positions on the Use of Artificial Sweeteners. 
Study Study Questions Study Design, Subjects Results Conclusions 
Nettleton, 
Lutsey, 
Wang et al 
(2009) 
Association btw diet 
soda consumption 
and risk of incident 
metabolic 
syndrome and type 
2 diabetes 
Population-based prospective 
cohort study, 3 follow up 
examinations every 2 years to 
identify T2D up to 7 years. 
6184 white, African American, 
Hispanic, Chinese adults age 
45-84 enrolled in MESA study 
Daily consumption of diet soda was associated with 
36% greater relative risk of incident metabolic 
syndrome and 67% greater relative risk of incident 
type 2 diabetes compared with non-consumption. 
Adjustment for baseline differences in waist circ and 
BMI slightly attenuated risk of developing T2D but 
results still statistically significant. 
Diet soda is associated with development 
of high fasting glucose and waist 
circumference during follow up but not 
with other metabolic syndrome risk 
factors suggesting metabolic syndrome 
associations are driven more by a pre-
diabetic condition. Diet soda consumption 
may lead to weight gain, impaired glucose 
control, and eventual diabetes. 
Collison, 
Makhoul, 
Zaidi (2012) 
Effect of lifetime 
exposure to 
aspartame starting 
in utero, on weight 
gain, insulin 
sensitivity and 
glucose parameters 
of mice. 
RCT. Split mice into two 
groups: standard chow plus 
water, and standard chow 
plus aspartame. 
Male and female mice, 
exposure to aspartame 
starting in utero, ITT at 19 
weeks of age 
Water/food intake unaffected by aspartame 
compared to controls. Random-fed insulin tolerance 
test showed glucose levels in male aspartame-fed 
mice were 120.2% higher than control mice 
following insulin challenge; remained significantly 
elevated above controls for up to 30 minutes. 
Aspartame impairs glucose and insulin 
regulation, as well as deregulates glucose 
homeostasis. Collectively data indicates 
aspartame treatment affects mice weight 
gain (6–17 weeks of age), visceral fat 
deposition and glucose homeostasis 
particularly in males, and to a lesser 
extent in females. 
Pepino, 
Tiemann, 
Patterson 
(2013) 
Acute effects of 
sucralose ingestion 
on the metabolic 
response to an oral 
glucose load in 
obese subjects 
Randomized crossover design. 
Modified oral GTT after 
consuming sucralose or water 
10 min prior to glucose load. 
17 obese Caucasian and 
African American male 
subjects who don’t use AS and 
are insulin sensitive 
Mean peak plasma glucose concentration was 
higher and subsequent drop was lower after 
sucralose compared to water ingestion. Peak plasma 
insulin and C-peptide concentrations were higher 
after sucralose ingestion. Differences in plasma 
glucose concentration between conditions caused a 
higher peak in the ISR after sucralose than after 
water, due to an average increase of static ISR. 
Sucralose affects the glycemic and insulin 
responses to an oral glucose load in obese 
people who do not normally consume 
NNS. Sucralose is not metabolically inert 
but has physiologic effects. 
Swithers, 
Sample, 
Davidson 
(2013) 
Association btw AS 
intake and 
increased food 
intake and body 
weight gain in 
female rats; 
Whether effect 
depends on 
composition of 
maintenance diet 
and or the 
phenotype of rats  
RCT 
Rats fed HFD to establish DIO 
versus DR rats. Rats randomly 
assigned to HFD and saccharin 
sweetened yogurt or glucose 
sweetened yogurt groups. 
Two different phenotypes in 
rats: diet-induced obese (DIO) 
and Diet resistant (DR) rats. 
Female rats fed low-fat chow diet did not gain extra 
weight when fed saccharin supplements compared 
to those fed glucose supplements. Female rats on 
HED had significant increases in energy intake, 
weight gain and adiposity when given saccharin 
compared to glucose. Differences most pronounced 
in female DIO rats – weight gain significantly greater 
in rats consuming saccharin compared to glucose. In 
DR rats, weight gain unaffected by sweetener type. 
Male rats fed HED - saccharin supplements 
produced extra weight gain regardless of obesity 
phenotype. 
Negative consequences of consuming 
high-intensity sweeteners may occur in 
those most likely to use them for weight 
control, females consuming a 
“Westernized” diet and already prone to 
excess weight gain. Increases in food 
intake, body weight gain and adiposity in 
animals given the saccharin-sweetened 
yogurt appear to result from 
overconsumption of the maintenance 
chow provided along with the yogurt, not 
overconsumption of yogurt itself. 
Suez, 
Korem, 
Zeevi et al 
(2014) 
NAS-mediated 
modulation of 
microbiota 
composition and 
function, resulting 
effects on host 
glucose 
metabolism. 
Randomized Control Trials. 
10 week old Male mice 
 
Human studies: 
381 non-diabetic male and 
female adults 
 
 
7 adult male and female 
 
Commercial/pure saccharin associated with IGT 
after HFD initiation. HFD mice suppl. with or without 
pure saccharin showed significant glucose 
intolerance after 5 weeks of saccharin exposure 
compared to controls. After 4 wks of antibiotic tx, 
differences in glucose intolerance between AS-
drinking mice and controls were abolished in lean 
and obese states. Saccharin tx induced large change 
in microbial relative abundance. Trnsfr of saccharin-
treated microbiota into germ-free mice resulted in 
significantly higher glucose intolerance compared to 
those receiving control culture. Significant positive 
correlation between human AS consumption and 
metsyn clinical parameters. Human trial resulted in 
responders and non-responders to saccharin.  
Consumption of saccharin drives 
development of glucose intolerance 
through induction of compositional and 
functional alterations to intestinal 
microbiota accounting for glucose 
intolerance phenotype in mammals. 
Collectively results link NAS consumption, 
dysbiosis and metabolic abnormalities, 
calling for a reassessment of massive NAS 
usage. Humans exhibit a personalized 
response to NAS, possibly stemming from 
differences in microbiota composition and 
function. 
Frankenfeld
, Sikaroodi, 
Lamb et al 
(2015) 
Gut microbiome in 
relation to recent 
high-intensity 
sweetener 
consumption in 
healthy adults. 
Cross-sectional. 4-day food 
record and fecal sample on 5th 
day. Age 18+ males and 
females. 31 participants. 
Average body mass index was 
24.3 
No significant differences in medians/ranges of 
relative abundance of bacteria across 
aspartame/ace-K nonconsumers/consumers but 
overall bacterial diversity was different the two 
groups. Bacterial diversity differences were 
significant across consumers/ nonconsumers of both 
sweeteners. 
Microbiome profiles may be related to 
long-term intake rather than short-term. 
Bacterial abundance profiles and 
predicted gene function not associated 
with recent AS consumption. Bacterial 
diversity differed across consumers and 
nonconsumers. 
  
AS dietary recommendations from national health organizations 
In light of the recent literature concerning the effect artificial sweeteners may have on 
weight gain and glycemic/insulin response, we reevaluated the evidence used to inform 
nutrition recommendations of the AND, ADA, and AHA. In Table 1, we summarize position 
statements on the health and safety of artificial sweeteners of the AND, ADA, and AHA. The 
current recommendations for Type 2 Diabetics to replace sugar sweetened beverages with 
artificially sweetened diet beverages as a way to control glycemic response and manage weight 
are largely based on position statements of several health organizations2,3,5 that have not 
incorporated recent literature on potential risks. All three health organizations cited many of 
the same sources in the position statements, and several of the studies included  are more than 
10 years old23-30, while Americans’ consumption of AS has increased greatly since 199931,32. 
Furthermore, the body of literature reviewed by the AND, ADA, and AHA to form their positions 
on the health value of artificial sweeteners is limited to human studies, though several recent 
animal studies provide mechanistic insights that bolster the evidence from observational 
studies21,33. Among the human studies referenced by the AND, AHA, and ADA, there are 
inconsistent findings regarding the role of AS in metabolic risk26,34-37. 
 The AND concluded that in a limited number of human studies, AS had no effect on 
changes in lipid profiles and glycemic response in adults with diabetes2. Several studies 
reviewed show that sucralose consumption did not adversely affect blood glucose 
control23,24,35,38, however sample sizes were small for many of these trials, and amounts of 
sucralose used were not consistent across the studies. One study found that diet beverage 
consumption was significantly, positively associated with increased HbA1c57. Some limitations 
to the AND conclusions include that they only reviewed studies that observed the effects of 
sucralose, and recruited subjects with diabetes who by definition have an impaired glycemic 
response related to insulin resistance. Results from their review may be extrapolated to people 
with T2D. Several of the studies failed to control for important confounders such as overall diet 
quality and caloric intake. The AND graded the literature used to support their conclusions 
about glycemic response to artificial sweeteners as “limited”. Of the studies the AND reviewed 
that looked at weight loss, several report no observable weight loss in consumers of AS 
compared with non-consumers26-28,36. The AND concludes that the use of AS will “affect overall 
energy balance only if AS-sweetened foods are substituted for higher-energy food or 
beverages”2. In other words, AS consumption will only lead to weight loss if the caloric 
reduction is not compensated for, and AS does not cause weight gain. The AND rated their 
evidence for aspartame’s ability to assist with weight loss as “good”, while evidence for 
saccharin and sucralose was rated as “limited”.  
The health organizations employed different methods to formulate their respective 
position statements. The AND relied heavily on FDA approval of AS (AND), while the ADA/AHA 
conducted a broader literature review on all potential factors affected by AS.  There is 
significant overlap in the sources cited by each organization, and the two papers cite one 
another to substantiate their conclusions. The ADA/AHA acknowledged that findings across 
studies have been inconsistent, and cited evidence that both supported their position with null 
or inverse associations24,25,34,37-40,45,59,60, and negated their position by showing AS to be 
positively associated with weight gain and impaired glycemic response29,30,61. Three of the 
studies reviewed by the ADA/AHA in regards to glycemic response overlap with those cited by 
the AND24,34,38, while two additional studies review the effects of stevia39,40, an AS that has not 
been granted GRAS status41 has not been greatly studied.  
These health organizations use the fact that there is limited evidence that AS 
consumption is unhealthy, paired with GRAS status established by the FDA42, to make the 
conclusion that AS are therefore acceptable or even a healthy option37,43,44. Citing a review of 
16 trials that focus on aspartame45, the ADA/AHA stated that “use of products with NNS results 
in weight loss or has negligible effects on weight”. However, weight loss was not a primary 
outcome almost half of the studies in the review, and “negligible effects” does not translate to 
“healthy” or “safe”. Furthermore, the ADA/AHA highlighted a study that found a positive dose-
response association between diet beverage consumption and incident overweight and 
obesity29, but due to the non-representative study sample and limitations to dietary 
assessment, they maintained their position that AS are healthy. Confronted with the finding 
from epidemiological studies that diet beverage consumption correlates with weight gain, 
diabetes, and metabolic syndrome, it is often concluded that that diet product consumption is 
initiated in response to a diagnosis or health condition, and not the other way around4,5,46. The 
ADA/AHA caution that reverse causality may be at play in the epidemiology studies they cite 
that report a positive relationship between AS and metabolic syndrome and cardiovascular 
events47,58,62. However, literature published since these position statements introduces the 
concept that artificial sweeteners are not inert substances as we once thought22,63-66. While we 
do not absorb AS from the intestinal tract (with the exception of aspartame), they still appear 
to influence blood glucose and insulin levels22.  
 
Growing support for possible AS-associated metabolic risks 
 Based on a literature search with the previously listed search terms, 6 recent studies on 
AS were identified and reviewed (Table 2), 5 of which were published after the position 
statements of the AND, ADA, and AHA were published. Studies were excluded if they used 
subjects other than humans or mice/rats, and if they explored AS associations with factors 
other than weight and glycemic/insulin response, or if they were included in the health 
organizations’ reviews. One population-based prospective cohort study reported that diet soda 
consumption is strongly associated with metabolic syndrome risk, elevated fasting glucose 
levels, and increased waist circumference20. Diet quality and obesity phenotype were reported 
to influence the effect of artificial sweeteners on body weight gain and glycemic response in 
three studies21,22,33. Three studies found significant associations between artificial sweeteners 
and glucose intolerance and weight gain in mice/rats21,33,48, while two studies report that this 
association is mediated by the gut microbiome21,49. The findings from these studies will be 
discussed in greater detail below. 
Epidemiological research that explores diet beverage consumption and T2D risk factors 
in humans (weight gain, metabolic syndrome, insulin resistance) shows the two factors are 
positively correlated over time, though researchers hesitate to confirm a directional 
relationship20,47,50. Using a large population-based prospective cohort study, Lutsey et al. 
evaluated the relationship between incident metabolic syndrome and dietary intake. They 
concluded that Western dietary patterns promote the incidence of metabolic syndrome and 
that diet soda consumption appeared to be an important component of this association. These 
findings were consistent with those from the Framingham Heart Study50, in which participants 
who consumed 1 or more serving of diet soda daily had an increased risk of developing 
metabolic syndrome.  
 Nettleton et al20 designed a study to specifically explore the relationship between diet 
soda intake and risk of incident metabolic syndrome and T2D. Using a large prospective cohort 
study design they followed participants for up to 7 years and periodically collected FFQs, 
anthropometric data, and fasting blood glucose levels. They found that compared to non-
consumers, at least daily consumers of diet soda had a 36% increased relative risk of incident 
metabolic syndrome. After adjusting for baseline differences in waist circumference and BMI 
the association lost its significance. This can be interpreted in two ways: first that weight is a 
complete confounder to the relationship between diet soda consumption and metabolic 
syndrome risk, or that in the population studied, weight lies on the causal pathway. Diet soda 
consumption was associated with the development of elevated fasting blood glucose and waist 
circumference, and was not associated with other metabolic syndrome risk factors: a specificity 
of findings that argues against confounding by overall health status. Compared to non-
consumers, daily consumers of diet soda had a 67% increased relative risk of developing T2D. 
The association between diet soda consumption and T2D remained significant across increasing 
doses of diet soda and was slightly attenuated after controlling for confounders. Nettleton and 
colleagues concluded that diet soda is associated with an increased risk of development 
elevated fasting glucose and waist circumference, but is not associated with other metabolic 
syndrome risk factors. Findings were strengthened by the study design, sample size and length 
of follow up, and confounders such as energy and food/nutrient intake (specifics not provided), 
time spent being active, and measures of adiposity were controlled for during analysis. One 
major flaw in this study is that researchers combined diet sodas into the same category as 
“unsweetened mineral water” when designing the FFQ. Unsweetened mineral water does not 
contain AS, and could otherwise be categorized as simply water. Sweetened mineral water 
(non-diet) was understandably grouped with other SSBs, however this means that artificially 
sweetened mineral water was not captured during data collection. Furthermore, unsweetened 
mineral water and diet soda may be consumed by people who have very different lifestyles and 
habits from each other, possibly introducing bias into the findings. The results of this study are 
likely attenuated by the categorization of beverage consumption. 
Collison et al48 designed a study to explore the effect of lifetime exposure to aspartame 
on weight gain, spatial cognition, insulin sensitivity, and glucose parameters in mice. Using a 
randomized control trial, they split mice into two groups: one exposed to standard chow and 
water, the other to standard chow and aspartame. Exposure began in utero (parent either 
consumed aspartame water or not) and random-fed insulin tolerance tests, overnight fasting 
glucose tests, and insulin checks were performed at 19 weeks of age. Water and food intake 
was unaffected between the two groups, however the ITTs in male mice showed glucose levels 
were 120% higher than controls for 30 minutes following the insulin administration. Aspartame-
fed mice also had elevated fasting blood glucose levels compared with non-consumers.  Fasting 
insulin levels were within normal range for all mice. Weight gain was significantly higher in male 
mice exposed to aspartame compared to controls, while female aspartame-consumers were 
unaffected. Aspartame-fed mice of both genders experienced increased body length and 
visceral fat deposition, and male consumers also had livers that weighed more than controls. 
Collison concluded that chronic exposure to aspartame impairs glucose and insulin regulation, 
and therefor negatively impacts glucose homeostasis. Aspartame also affects mouse weight 
gain and visceral fat deposition, particularly in males. Researchers noted that male mice 
experienced more adverse effects from aspartame than females. This study provides good 
evidence that lifelong exposure to artificial sweeteners can have an impact on the glycemic 
response of mice. The results of this study would be strengthened if a similar study was 
conducted in which the mice were given different diets to follow within each group. 
 
Possible heterogeneity in response to AS 
In several of the new studies reviewed, researchers found that in the context of a 
Western diet pattern high in sugar and fat21,47, or an obesity-prone phenotype22,33, artificial 
sweetener consumption correlates with an impaired glycemic response and/or weight gain. 
Studies that include a population with a healthy body weight or subjects that follow a healthy 
diet pattern find weak or non-significant relationships between AS and weight gain or glycemic 
response21,33,49 . The implication here is that diet pattern and body weight may be modifiers in 
the relationship between AS consumption and the development of T2D risk factors.  
Pepino et al22 evaluated the acute effects of sucralose ingestion on the metabolic 
response to an oral glucose load in obese humans. Using a FFQ they assessed potential AS 
intake in any form to identify 17 subjects from a pool of insulin sensitive, obese volunteers that 
never consume AS. In a randomized crossover approach, researchers administered modified 
oral glucose tolerance tests to subjects after consuming sucralose or water 10 minutes prior to 
a glucose load. They monitored indices of beta cell function, insulin sensitivity, glucose 
concentrations, and insulin clearance rates at various intervals from 10 minutes before through 
300 minutes after glucose consumption. Beta cell function was determined by insulin secretion 
response (ISR). Results showed that in comparison to post-water consumption, mean peak 
plasma glucose concentrations were higher, and the subsequent drop was lower, after 
sucralose consumption. Along with glucose, peak plasma insulin and C-peptide concentrations 
were also higher after ingestion of sucralose, and insulin clearance from plasma was slower. 
The differences in plasma glucose concentrations caused a higher peak in the ISR, specifically 
static ISR (the slower release of insulin in response to ambient blood glucose concentration 
from a reserve pool), after sucralose consumption in comparison to water consumption. Pepino 
concluded that sucralose affects the glycemic and insulin responses to an oral glucose load in 
obese subjects who to not normally consume AS, and that sucralose is not metabolically inert. 
Artificial sweeteners enhance glucose stimulated insulin secretion in obese people.  
Pepino and colleagues point toward their decreased variability in study subjects as a 
strength of their study. Focusing on obese individuals lends to its statistical power of the results 
that sucralose affects glycemic and hormonal responses to a glucose load.  That being said, the 
results can only be extrapolated to other obese individuals who are not regular users of 
nonnutritive sweeteners. Another strength is that the Pepino study did an exhaustive 
exploration of all possible consumption to rule out any AS consumers by asking participants 
about beverage, processed food, diet products consumption, as well as gum use. It does not 
appear that they controlled for other dietary habits, however, which is a limitation of the study. 
As with many of the other studies reviewed, the sample size is small. Validity of the results 
would be strengthened if repeated with more participants. 
 In order to explore whether intake of AS is associated with increased food intake and 
body weight gain, and whether this effect depends on diet composition and/or obesity 
phenotype, Swithers et al33 performed a randomized control trial in rats. They established 
phenotype first by feeding all rats a high energy diet (HED) high in sugar and fat. Diet-induced 
obese (DIO) rats gained large amounts of excess weight, while diet resistant (DR) rates 
experienced minimal weight gain, when fed a HED relative to weight gained on a standard low-
fat chow diet. Rats were further divided to receive either saccharin or glucose sweetened 
yogurt supplements. Initial experiments focused on female rats while later experiments focused 
on males. Female rats fed a standard chow diet did not gain extra weight when fed saccharin-
sweetened yogurt supplements sweetened compared to those fed supplements sweetened 
with glucose. Body weight gain, energy intake, and adiposity in female DIO rats was significantly 
greater in those consuming saccharin sweetened yogurt compared to glucose consumers 
starting on day 10 of the experiment. In DR rats, weight gain and fat mass were unaffected by 
the sweetener provided. Male rats fed a HED in conjunction with saccharin supplements 
experienced extra weight gain regardless of their obesity phenotype. There was no difference in 
grams of yogurt consumed across sweeteners or phenotype, rather the increased caloric intake 
in the saccharin-supplemented rats came from increased consumption of the chow diet. 
Compared to rats receiving glucose supplements, both the DIO and DR groups given saccharin 
supplements consumed a greater number of calories from the HED. Of the group of rats fed a 
HED along with glucose-sweetened supplements, the DIO and DR rats all consumed a similar 
number of calories. For saccharin-supplemented rats, the DIO rats took in significantly more 
calories than the DR rats. Swithers and colleagues established that phenotype differences in 
propensity toward obesity on a high energy diet interacts with effects of saccharin exposure to 
disrupt the predictive relation between sweet taste and calories. When sweet taste no longer 
serves as a reliable energy predictor, rats with an obesity-prone phenotype overconsume 
calories and gain more weight compared to diet resistant rats. It is difficult to generalize the 
results to humans who are more variable in their food choices and weight regulation. This study 
exposes a possible relationship between saccharin consumption and altered dietary 
consumption habits in rats that may also be present in humans. To confirm the translational 
value of animal studies, future research should conduct RCTs such as this with human subjects. 
 
Possible mechanism for AS and metabolic risk 
The correlation between AS intake and impaired glycemic response in the context of 
poor diet quality and obesity may be mediated by our gut microbiota. It has been shown that 
increased gut microbial diversity and the presence of butyrate-producing microbiota improves 
insulin sensitivity51. Increased microbial diversity is correlated with a healthy body weight and 
improved insulin sensitivity, while individuals with metabolic syndrome, an unhealthy body 
weight, or consume a high fat diet have a less diverse gut bacteria21,49,52. The direction of the 
relationship between microbiota and weight is unclear, as each seems to impact the other53,54. 
Possible directionality is addressed by a growing body of research exploring the influence 
artificial sweeteners have on intestinal microbiota and the microbiome’s diversity, as well as 
glycemic response, insulin resistance, and weight gain21,49,52. 
 Suez et al21 published a landmark study demonstrating that artificial sweetener 
consumption, specifically saccharin, alters glucose intolerance in mice, driven by the 
composition and function of intestinal microbiota. A series of experiments comparing artificial 
sweetener consumption with that of glucose, sucrose, and water revealed that saccharin, 
sucralose, and aspartame induced significant glucose intolerance in lean, 10 week old mice 
compared to controls. Saccharin had the most pronounced effect and proceeding experiments 
focused on this artificial sweetener. Researchers divided mice into two diet groups: normal 
chow and high-fat chow. Within these groups mice were fed either commercial saccharin, pure 
saccharin proportionate to the amount approved by the FDA for human consumption, or a 
control solution of glucose, sucrose, or water. After five weeks researchers observed that mice 
in both diet groups consuming commercial and pure saccharine solutions had elevated blood 
glucose levels compared to controls. Furthermore, the saccharin-consuming mice had a 
microbiota composition that clustered separately from their starting microbiome as well as 
from the microbiomes of all control groups. After treating these mice with antibiotics for four 
weeks, the difference in glucose tolerance between saccharin consumers and controls 
disappeared. Next, researchers performed fecal transplants between mice on normal chow or 
high fat diets drinking either saccharin or control into germ free mice consuming a normal chow 
diet. After 6 days mice that received microbiota from saccharin-consumers had an impaired 
glucose tolerance when compared with mice that received transplants from controls. The 
recipients of saccharin-consumers’ stools had microbiota that clustered separately from the 
microbiota of those that received control group stool. Suez concluded that artificial sweeteners 
impose compositional modifications to microbial diversity, and gut microbiota mediates 
artificial sweetener-induced glucose intolerance.  
 Finally, Suez et al explored the effect of AS consumption on humans. FFQs completed by 
381 non-diabetic adults and corresponding clinical measures showed a significant positive 
relationship between AS consumption and elevated HbA1c levels, and other metabolic 
syndrome risk factors. No causal relationship could be established from this due to the cross-
sectional design of this study. To explore a causal pathway between AS and impaired glucose 
tolerance, Suez recruited 7 healthy, non-AS consuming individuals to consume maximum-
approved doses of saccharin for 5 days (7 days from baseline to finish). Four of the 7 
participants experienced marked alterations in glycemic response and compositional changes 
to their intestinal microbiota. The remaining 3 individuals experienced little to no change in 
glycemic response and microbiome composition after AS consumption. At baseline, participants 
that “responded” to high doses saccharin had a different microbial composition than the “non-
responders”. Researchers transferred baseline and exposed stool samples from all 7 subjects 
into germ free mice. Recipients of the “responders” stool samples experienced similar glucose 
intolerance and compositional changes to their gut microbiome. While humans are different 
mammals than mice, these findings are compelling. The design of the mouse studies controls 
for many potential confounders often present in human studies (such as diet, lifestyle, income, 
education, etc.), and establish a directional relationship between AS and glycemic response. 
Results in all mouse experiments were controlled for liquid, chow, and oxygen consumption, 
walking distance and energy expenditure, as well as fasting insulin levels and insulin tolerance 
during data analysis. The results from the human experiments are less valid than the mouse 
studies as researchers did not control for diet and lifestyle confounders that may impact the 
outcome of glycemic response. While the findings are significant, the sample size was very 
small, and study duration very short. Repeated in a larger sample beyond 7 days and with 
consideration of confounding factors, this study design has the potential establish a more solid 
association with directionality.  
 Frankenfeld et al49 used a cross sectional study design In order to evaluate the gut 
microbiome in relation to recent AS consumption, specifically aspartame and acesulfame K, in 
healthy adults (average BMI of 24.3 kg/m2). Participants recorded a 4-day food record then 
submitted a fecal sample on day 5. Researchers calculated subjects’ healthy eating index as a 
measure of diet quality, and analyzed the composition of each gut microbiome. They found no 
differences in the ranges of relative abundance of bacteria and gene function across consumers 
and non-consumers of aspartame and acesulfame K. However, there was a significant 
difference in overall bacterial diversity across aspartame non-consumers, consumers, and 
consumers of both sweeteners. Frankenfeld concluded that while there were differences in 
bacterial diversity in the subjects, short term intake of artificial sweeteners does not impact 
relative abundance of gut bacteria. They reason that it is possible microbiome profiles may be 
related to long-term intake of artificial sweeteners rather than short-term intake, but they do 
not know the long term intake status of their participants. Because they only measured short 
term intake of artificial sweeteners does not mean they can assume what their subjects’ long 
term intake patterns are. This is a weak study that does not establish directionality in the 
relationship between artificial sweeteners and the gut microbiome. It does not appear that 
researchers controlled for confounders, such as diet quality. Consumption of artificial 
sweeteners could be different across dietary patterns. The potential for reverse causality is 
mitigated however, by the fact that participants are all healthy. They do not have a chronic 
condition such as diabetes or obesity that causes them to turn to diet products. That being said, 
BMI is their only measure of health status. We do not know what other conditions may be 
present. Due to the small sample size, participants were dichotomized as consumers vs. non-
consumers, missing the potential for a dose-response of AS consumption. Overall consumption 
of AS in this sample was also low as noted by researchers.  
The collective findings from these studies speaks to the synergistic effect of diet and 
lifestyle in conjunction with artificial sweetener consumption. If poor diet and lifestyle are 
precursors to the development of T2D, it appears that the addition of artificial sweeteners to 
the diet may exacerbate this effect, and possibly expedite a chronic disease diagnosis. 
Conversely, consuming a healthy diet and maintaining a healthy body weight appear to 
minimize the effect AS consumption has on T2D risk factors and the gut microbiota. 
There is a great need for future studies in the area of artificial sweeteners and their 
relationship to weight gain, glycemic response, and other risk factors associated with T2D. 
While current studies of the interaction between AS and intestinal microbiome in mice produce 
valid and significant findings, similar studies should be replicated in humans. Of the microbiome 
studies that have been conducted with humans, many have small sample sizes and focus on 
short term effects of AS on insulin response/weight management. Future studies should include 
larger sample sizes and continue beyond a few weeks or months. There is also a need for more 
consistency in the inclusion and exclusion criteria in research involving human subjects. Some 
studies remove anyone who smokes, has a GI disorder, etc. while others do not address these 
factors. Consistent control for comorbidities that affect the microbiome and risk factors of 
interest will help produce significant results. Longitudinal cohort studies that assess diet 
beverage consumption as an exploration of AS intake need better control for overall diet 
content and quality as potential confounders. Those that consume AS may be consuming 
fundamentally different diets from non-consumers of diet products, which is something that 
epidemiological studies have yet to uncover. Lab studies of mice report a directionality in the 
relationship between AS and glycemic response that human studies have not yet provided. It 
must be kept in mind that artificial sweeteners are metabolized differently, and should be 
considered as separate substances when exploring the effect they have55. Conclusions made 
from studies exploring individual sweeteners cannot be extrapolated to artificial sweeteners as 
a whole. Finally, humans who consume diet products may do so for reasons of health and 
weight maintenance, and may follow a different diet pattern that collectively influences 
findings. Future studies need to explore the humans’ diet beverage and food consumption 
behaviors to help guide resulting public health policies.  
  
Summary 
The studies reviewed highlight the notion that the people who are more likely to 
consume AS, those already at an increased risk of developing insulin resistance and type 2 
diabetes, are the very people who should be avoiding these products. The potentially negative 
effects of AS consumption on weight management may differentially impact obesity-prone 
females consuming a Western diet, as they are most likely to consume diet products33. For 
patients who do not control their T2D through diet, the recommendation to consume diet 
beverages for glycemic control may in fact exacerbate their impaired glycemic response and 
weight issues. Dietitians and clinical practitioners should take this new evidence into account, 
and perhaps reevaluate the clinical guidelines that dictate the dietary recommendations we 
make for patients with metabolic syndrome and T2D. We need to consider the fact that the 
majority of Americans do not follow the dietary guidelines6, rather most Americans consume a 
Western diet that has been shown to alter the diversity of the gut microbiome21,49,52.  
While diet products may aid in glycemic control and weight management for already 
healthy individuals, the same does not appear to be true for patients of an excessive body 
weight or who follow an unhealthy diet pattern. Until more research is done, it may be in the 
best interest of our patients to change our nutrition recommendations. That being said, as 
dietitians we need to meet our clients where they’re at, and it might not be realistic to cut out 
diet product consumption in addition to our many other recommendations. Furthermore, the 
strongest effects on glycemic response were observed with saccharin consumption, which is 
not as widely used as other artificial sweeteners.  
 We also need to consider diet soda consumption in the context of proposed public 
policies to curb sugar sweetened beverage (SSB) consumption. A price increase in SSBs in the 
US could result in increased diet soda consumption, an unintended negative consequence in 
light of recent findings. However there is some evidence that cross elasticity of demand for diet 
soda may decrease in response to a SSB tax56. As with most other publications, the findings in 
this review are compelling and deserve further research. In the mean-time it may be prudent to 
at least consider the potentially negative effects artificial sweeteners have on our health as 
enter the field of dietetics. 
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